Wakamoto Pharmaceutical Co.,Ltd. (TYO:4512)

Market Cap	10.58B
Revenue (ttm)	9.43B
Net Income (ttm)	-222.00M
Shares Out	34.79M
EPS (ttm)	-6.38
PE Ratio	n/a
Forward PE	n/a
Dividend	3.00 (0.93%)
Ex-Dividend Date	Mar 28, 2025

Volume	205,900
Average Volume	643,460
Open	304.00
Previous Close	304.00
Day's Range	302.00 - 310.00
52-Week Range	209.00 - 377.00
Beta	0.59
RSI	54.00
Earnings Date	Aug 5, 2025

About Revance Therapeutics

Wakamoto Pharmaceutical Co.,Ltd. manufactures and sells ethical and non-prescription drugs in Japan. The company offers Strong and Granule Wakamoto, gastrointestinal drugs for digestion, intestinal regulation, and nutritional supplementation; and Wakamoto Intestinal Remedy drug. It also provides AVANTBISE oral tablets, a supplement of bacteria to restore the balance of oral flora; and medicated toothpaste. The company was formerly known as Society for Nutrition and Raising Children Co., Ltd. and changed its name to Wakamoto Pharmaceutical Co.,L...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1929
• Employees: 403
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4512

Financial Performance

In 2011, Wakamoto Pharmaceutical's revenue was 9.43 billion, a decrease of -2.45% compared to the previous year's 9.67 billion. Losses were -222.00 million, -47.76% less than in 2010.